Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
Makaleler > Tam Makale · 2020
Yazarlar: Nazan Cobanoglu, Ugur Ozcelik, Erkan ÇAKIR, Tugba Sismanlar Eyuboglu, SEVGİ PEKCAN, Guzin Cinel, Ebru Yalcin, Nural Kiper, NAGEHAN EMİRALİOĞLU, VELAT ŞEN, HADİCE SELİMOĞLU ŞEN, Omur Ercan, Haluk Cokugras, Ayse Ayzit Kilinc, Lina Muhammed Al Shadfan, HAKAN YAZAN, DERYA UFUK ALTINTAŞ, DİLEK KARAGÖZ IŞIK, Esen DEMİR, Gokcen Kartal Ozturk, AYŞEN BİNGÖL, Abdurrahman Erdem Basaran, NİHAT SAPAN, ŞÜKRÜ ÇEKİÇ, EBRU ÇELEBİOĞLU, AYŞE TANA ASLAN, Tugba Ramasli Gursoy, Gokcen Tugcu, Ali Ozdemir, KORAY HARMANCI, Gonca Kilic Yildirim, MEHMET KÖSE, Melih Hangul, Zeynep Tamay, Ayse Suleyman, HASAN YÜKSEL, ÖZGE YILMAZ, Gizem Ozcan, ERDEM TOPAL, Demet Can, Pervin KORKMAZ, GÖNÜL ÇALTEPE, MEHMET KILIÇ, Sebnem Ozdogan, DENİZ DOĞRU ERSÖZ
PEDIATRIC PULMONOLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2020, cilt 55, ss 2302-2306
DOI: 10.1002/ppul.24854
Özet
Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.